EGFR突变非小细胞肺癌的个体化治疗:从早期到晚期疾病管理的导航
该综述概述了EGFR突变非小细胞肺癌的治疗格局,涵盖酪氨酸激酶抑制剂(TKI)在早期和局部晚期疾病中的应用、转移性疾病的联合策略、生物标志物(共突变和循环肿瘤DNA)对治疗选择的优化,以及耐药机制相关治疗选择的拓展。
要点
- TKI已纳入早期和局部晚期EGFR突变NSCLC的管理,3期试验探索了转移性疾病的联合策略。
- 强化联合方案改善无进展生存,但毒性和成本增加,需精准选择患者以最大化获益。
- 共突变和循环肿瘤DNA等生物标志物数据有望优化治疗决策,耐药机制研究拓宽了治疗选择。
核心结论
- EGFR突变NSCLC的治疗格局已被TKI显著重塑,近期进展涵盖早期至晚期疾病管理。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- TKI已纳入早期和局部晚期EGFR突变NSCLC的管理,3期试验探索了转移性疾病的联合策略。
- 强化联合方案改善无进展生存,但毒性增加且成本更高,需精准选择患者以最大化获益。
- 共突变和循环肿瘤DNA等生物标志物数据有望优化治疗决策。
- 对EGFR TKI耐药机制的理解取得进展,拓宽了治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments. Recent advancements have significantly reshaped the treatment paradigm for EGFR-mutant non-small cell lung cancer. TKIs are now incorporated into the management of early stage and locally advanced disease, and phase 3 trials have explored combination strategies in metastatic settings. Although these intensified approaches improve progression-free survival, they come with increased toxicity and higher costs, underscoring the need for precise patient selection to maximize benefit. Emerging data on biomarkers, such as co-mutations and circulating tumor DNA, show promise for refining treatment decisions. In addition, significant progress in understanding resistance mechanisms to EGFR TKIs has broadened therapeutic options. This review provides a comprehensive overview of the current landscape of EGFR-mutant nonsmall cell lung cancer, highlighting recent breakthroughs and discussing strategies to optimize treatment based on the latest evidence.
引用
- Borgeaud M, Olivier T, Bar J, et al. Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management. CA Cancer J Clin. 2025. PMID: 40673977. doi:10.3322/caac.70024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。